# Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

> **NCT01945762** · — · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 31 (actual)

## Conditions studied

- Symptomatic, Aggressive, Sporadic, Unresectable, Locally
- Advanced/Metastatic Medullary Thyroid Cancer (MTC)

## Interventions

- **DRUG:** Vandetanib 300 mg

## Key facts

- **NCT ID:** NCT01945762
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-17
- **Primary completion:** 2020-06-18
- **Final completion:** 2020-06-18
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945762, "Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01945762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*